Product Images Losartan Potassium

The text contains data related to a study that compares the effectiveness of Atenolol and Losartan Potassium in reducing the risk of a primary endpoint in patients. The text shows a graph displaying the study month against the percentage of patients with the primary endpoint. Additionally, the text mentions an adjusted risk reduction of 13% with a p-value of 0.021.*

The text provides information on a comparison between Atenolol and Losartan potassium in terms of the percentage of patients who suffered from fatal/non-fatal strokes. The adjusted risk reduction percentage and p-value are also mentioned. The study tracked patients for a period of 66 months.*

The text describes the results of a study comparing the effectiveness of Losartan K and atenolol for preventing fatal/near-fatal strokes. The study involved participants of different genders, races, and medical histories, and the results showed a slight advantage for Losartan K. The study was adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

This is a summary of a clinical trial that compared the effectiveness of the drug Losartan Potassium (20r) to a placebo. The trial measured the risk reduction percentage, which was found to be 16.1%. The trial also reported a statistical significance level of p=0.022. The number 401 is likely a reference to the total number of patients included in the trial. The meaning of "asassss" is not clear and may be a result of error. The phrase "% patients with event" suggests that the trial measured the occurrence of some type of event, but without further context it is not clear what that event was.*